- Report
- May 2022
- 177 Pages
Global
From €3340EUR$3,500USD£2,799GBP
- Report
- May 2022
- 62 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Report
- May 2022
- 49 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Report
- May 2022
- 40 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Drug Pipelines
- April 2019
- 85 Pages
Global
From €3340EUR$3,500USD£2,799GBP
- Drug Pipelines
- November 2018
- 39 Pages
Global
From €3340EUR$3,500USD£2,799GBP
- Report
- January 2025
- 132 Pages
Global
From €907EUR$950USD£760GBP
- Report
- September 2022
- 242 Pages
Global
From €3407EUR$3,570USD£2,855GBP
- Report
- July 2022
- 274 Pages
Global
From €3522EUR$3,690USD£2,951GBP
- Report
- June 2022
- 230 Pages
Global
From €3298EUR$3,456USD£2,764GBP
The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more